SWITZERLAND – Consortium of investors raise CHF 17m for Vivendy
BioMedInvest AG I, LSP Life Sciences Partners and TVM Capital closed a CHF 17m series-A round for Vivendy Therapeutics Ltd., a bio-pharmaceutical company located in Basel, Switzerland. Vivendy is a pharmaceutical start-up company that is developing an enzyme replacement therapy (ERT) for Morbus Morquio (Mucopolysaccharidosis (MPS) IVA), a rare lysosomal storage disease. It was founded in 2006 as a spin-off from Inotech Biotechnologies AG.
More on Early-stage
Osivax raises €33m from EIC and BPI France
Of the funding, €15m from EIC will count towards series-B funding, while the rest will be a grant
Alta Life Sciences, Kurma lead €3.5m series-A for Deepull
Axis Participaciones and Sofimac Innovation, through Pertinence Invest 2, also take part in the round
ETF leads €7m round for Basemark
Fresh capital will be used to accelerate Basemark's growth in the field of autonomous vehicles
Seventure, BioGeneration lead €18.5m round for Citryll
Pharma company has so far raised €33.5m from private backers
Latest News
EMZ 9 closes on €1.04bn
EMZ recently opened its first international office in Munich, headed by partner Klaus Maurer
Nauta Tech Invest V holds €120m first close
Fund deploys tickets of €1-5m in seed and series-A rounds to support European B2B SaaS startups
Capza to acquire Eurofeu
French GP is planning to take exclusive control of the fire safety specialist
Goldman Sachs Growth leads $80m series-D for LeanIX
Insight, Deutsche Telekom Capital Partners, Capnamic and Iris Capital also participate